NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.12 against a street estimate of -1.00 — a beat of 112.0%.
with an average price target of ₹566.00.
| Document | Date |
|---|---|
| Annual report FY2026 SOLARA ACTIVE PHARMA SCIENCES LIMITED - FY2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹1,368.98 crores (YoY growth 6.6%) • EBITDA: ₹ | 2026-08-25 |
| Quarterly results · Q1 FY27 SOLARA ACTIVE PHARMA SCIENCES LIMITED – Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 FY2027 Consolidated Profit: Rs 16.31 crores (net profit af | 2026-07-24 |
| Q4 FY26 earnings call SOLARA ACTIVE PHARMA SCIENCES LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 392 crores with 12% quarter-on-quarter growth • Q4 F | 2026-05-21 |
| Quarterly results · Q4 FY26 SOLARA ACTIVE PHARMA SCIENCES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue: Rs 1,368.98 Crores (up 6.6% from Rs 1,283.76 | 2026-05-15 |
| Q3 FY26 earnings call SOLARA ACTIVE PHARMA SCIENCES LIMITED – Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 346 crores, representing 10% sequential (Q- | 2026-02-10 |
| Quarterly results · Q3 FY26 SOLARA ACTIVE PHARMA SCIENCES LIMITED - Q3 FY2026 SUMMARY HEADLINE NUMBERS • 9 months ended Dec 31, 2025 (Consolidated): Revenue Rs. 981.69 crores | | 2026-02-06 |
| Q2 FY26 earnings call SOLARA ACTIVE PHARMA SCIENCES LIMITED – Q2 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 FY26 Revenue: INR 314 crores (2% Q-o-Q marginal decline) • Gr | 2025-11-11 |
| Quarterly results · Q2 FY26 SOLARA ACTIVE PHARMA SCIENCES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY2026 (Quarter ended Sept 30, 2025): Revenue from operations Rs 313 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Solara Active Pharma Sciences Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.